RPS17 can act as a tumor suppressive ribosomal protein in human cell lines
The Journal of Biochemistry · 05.11.2026
DOI: 10.1093/jb/mvag083 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Biochemistry, online erschienen am 05.11.2026. Verfasst von Takuya Takafuji und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Jap….
Abstract (Originalsprache)
Certain ribosomal proteins (RPs) function as tumor suppressors. For example, RPL5 and RPL11 suppress oncogenesis by binding to MDM2 and thereby up-regulating p53, a mechanism referred to as the RP-MDM2-p53 cascade. However, whether other cancer-associated ribosomal proteins actually function as tumor suppressors has remained largely unclear. Previously, we showed that siRNA-mediated silencing of RPS17, in combination with expression of HPV16 E7 and activated KRAS G12V, transformed normal human fibroblasts. Here, we expanded our study to perform a functional analysis of RPS17 as a tumor suppressor. We first demonstrate that shRNA-mediated RPS17 silencing also promotes oncogenic transformation of human fibroblasts in vitro and in vivo. Conversely, its overexpression inhibits the soft agar colony formation of colon cancer-derived HCT116 cells in a p53-dependent manner. RPS17 weakly interacts with MDM2. However, unlike RPL5 and RPL11, overexpression of RPS17 does not increase p53 levels and its silencing induces p53, suggesting that the RP-MDM2-p53 cascade might not be a major pathway for its tumor-suppressive function. We further show that RPS17 binds to nucleophosmin and modulates its nuclear localization. Although the detailed molecular mechanisms underlying the tumor-suppressive function of RPS17 remain to be elucidated, this study provides evidence that RPS17 can function as a tumor suppressor.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
- Project for Prevention of HPV-related Cancer, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
- Division of Cell Signaling, Institute of Advanced Medical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
- Department of Pharmacology, Faculty of Medicine, Toho University, 5-21-16 Omori-Nishi, Ota-ku, Tokyo 143-8540, Japan.
ORCID-Profile: Hidetaka Kosako, Masatoshi Fujita
Zitieren
APA
Takafuji, T., Mori, Y., Tsutsui, N., Yanagi, N., Kiyono, T., Kosako, H., Katsuki, Y., Sugimoto, N., & Fujita, M. (2026). RPS17 can act as a tumor suppressive ribosomal protein in human cell lines. The Journal of Biochemistry. https://doi.org/10.1093/jb/mvag083
Vancouver
Takafuji T, Mori Y, Tsutsui N, Yanagi N, Kiyono T, Kosako H, et al. RPS17 can act as a tumor suppressive ribosomal protein in human cell lines. The Journal of Biochemistry. 2026. doi:10.1093/jb/mvag083
BibTeX
@article{Takafuji2026,
author = {Takafuji, Takuya and Mori, Yukino and Tsutsui, Natsuka and Yanagi, Natsumi and Kiyono, Tohru and Kosako, Hidetaka and Katsuki, Yoko and Sugimoto, Nozomi and Fujita, Masatoshi},
title = {RPS17 can act as a tumor suppressive ribosomal protein in human cell lines},
journal = {The Journal of Biochemistry},
year = {2026},
doi = {10.1093/jb/mvag083}
}
EUVIMED